🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨Out now Clinical Cancer Research! We demonstrate accurate non-invasive detection of small cell transformation in EGFRm lung adenocarcinoma through epigenomic cfDNA profiling! Led by @Cbmeador Xintao & guided by Jacob Berchuck #MattFreedman Dana-Farber Mass General Cancer Center doi.org/10.1158/1078-0…

I can’t think of anyone more deserving of this recognition. Matt Freedman is an extraordinary scientist, mentor, and colleague who has made equally immense and indelible impacts on the field of cancer epigenetics / liquid biopsy and the careers and future success of his mentees.

WATCH: Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at #ESMO24. Jacob Berchuck Emory School of Medicine Winship Cancer Institute of Emory University targetedonc.com/view/epigenomi…

Challenging prostate cancer subtypes like liver metastases and neuroendocrine #prostatecancer may ultimately benefit from more precise treatment approaches, thanks to innovative liquid biopsy technology. Oliver Sartor & Jacob Berchuck discuss on @urotday- bit.ly/4ewKx4I

Novel epigenomic liquid biopsy detects PSMA expression in #ProstateCancer. Jacob Berchuck Winship Cancer Institute of Emory University and Oliver Sartor, MD Mayo Clinic dive into this cutting-edge epigenomic liquid biopsy platform that uses cell-free DNA to infer PSMA expression. This novel assay shows a strong

📊 Revolutionary approach: Analyzing cell-free DNA to track PSMA expression in real-time. Dr. Jake Berchuck (Jacob Berchuck) discusses how this could transform treatment decisions in prostate cancer. Watch the complete discussion on UroToday.com: tinyurl.com/e6aj8b38

Fantastic Clinical Cancer Research Translations piece from Jacob Berchuck & colleagues on our recent Clinical Cancer Research paper uncovering a stemness signature enriched in cfDNA in lethal AR-altered prostate cancer patients. Pradeep Chauhan Mayo Clinic Radiation Oncology Mayo Clinic Comprehensive Cancer Center Mayo Clinic aacrjournals.org/clincancerres/…

Thank you International Society of Liquid Biopsy for the opportunity to speak on the potential of liquid biopsies for early cancer detection at #ISLB24. Congrats to Christian Rolfo and co for organizing a fantastic conference!

Honored to be awarded best poster at the International Society of Liquid Biopsy #ISLB24 Annual Congress for our work using a novel epigenomic liquid biopsy platform to detect PSMA expression and predict Pluvicto response in mCRPC. CC: fantastic collaborators Praful Ravi Heather Jacene Precede Biosciences

Data presented at #ISLB24 suggest that epigenomic cfDNA may accurately assess PSMA expression and predict Lu-PSMA response in mCRPC. Jacob Berchuck Emory Urology #pcsm urologytimes.com/view/epigenomi…

Winship medical oncologist Jacob E. Berchuck, MD recently spoke with Targeted Oncology on how a new epigenomic platform may influence the accessibility of prostate-specific membrane antigen-based therapies. ➡️ brnw.ch/21wPMdh

Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in #mCRPC. Presentation by Jacob Berchuck Emory School of Medicine. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/43Qj5uG ASCO